Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2661-2667

  Huang, Shu Pin ^a,b   Levesque, Eric ^c   Guillemette, Chantal ^c   Yu, Chia Cheng ^d,e,f   Huang, Chao Yuan ^g   Lin, Victor C ^h,i   Chung, I Che ^j   Chen, Lih Chyang ^k   Laverdière, Isabelle ^c   Lacombe, Louis ^c   Fradet, Yves ^c   Chang, Ta Yuan ^l   Lee, Hong Zin ^l   Juang, Shin Hun ^l   Bao, Bo Ying ^l,m  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c LAVAL UNIVERSITY   (Canada)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAJEN UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h E DA HOSPITAL   (Taiwan)

ⁱ I SHOU UNIVERSITY   (Taiwan)

^j CHANG GUNG UNIVERSITY   (Taiwan)

^k MACKAY MEDICAL COLLEGE   (Taiwan)

^l CHINA MEDICAL UNIVERSITY   (Taiwan)

^m CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Biochemical recurrence; microRNA; Prostate cancer; Radical prostatectomy; Single nucleotide polymorphism

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 181C; MICRORNA 5007; MICRORNA 605; UNCLASSIFIED DRUG; LUCIFERASE; TUMOR MARKER;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; ASIAN; BIOCHEMICAL RECURRENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CAUCASIAN; CDON GENE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAZARD RATIO; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIR605 GENE; MTRR GENE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TARGETING; RETROSPECTIVE STUDY; RNA BINDING; RNA TARGETING SITE; SINGLE NUCLEOTIDE POLYMORPHISM; TREND STUDY; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROSTATIC NEOPLASMS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HUMANS; LUCIFERASES; MALE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84921625076     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28904     Document Type: Article

References (27)

1. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17: 1499-507.
2. Bismar TA, Humphrey P, Vollmer RT. Information content of five nomograms for outcomes in prostate cancer. Am J Clin Pathol 2007;128:803-7.
3. Shariat SF, Karakiewicz PI, Roehrborn CG, et al. An updated catalog of prostate cancer predictive tools. Cancer 2008;113:3075-99.
4. O'Kelly F, Marignol L, Meunier A, et al. Micro-RNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol 2012;9: 397-407.
5. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6:376-85.
6. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14:1-6.
7. Audet-Walsh E, Bellemare J, Nadeau G, et al. SRD5A polymorphisms and biochemical failure after radical prostatectomy. Eur Urol 2011;60: 1226-34.
8. Bao BY, Pao JB, Lin VC, et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta 2010;411: 1232-7.
9. Chang CF, Pao JB, Yu CC, et al. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Ann Surg Oncol 2013;20:2446-52.
10. Huang SP, Lan YH, Lu TL, et al. Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU Int 2011;107: 486-92.
11. Huang SP, Ting WC, Chen LM, et al. Association analysis of Wnt pathway genes on prostatespecific antigen recurrence after radical prostatectomy. Ann Surg Oncol 2010;17:312-22.
12. Nadeau G, Bellemare J, Audet-Walsh E, et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab 2011;96:E1550-7.
13. Yu CC, Lin VC, Huang CY, et al. Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 2013;20(Suppl 3): S492-9.
14. Griffiths-Jones S, Saini HK, van Dongen S, et al. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-8.
15. Grimson A, Farh KK, Johnston WK, et al. Micro-RNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;27:91-105.
16. Karolchik D, Hinrichs AS, Furey TS, et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res 2004;32:D493-6.
17. Bao BY, Pao JB, Huang CN, et al. Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer 2012; 130:876-84.
18. Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 2012;23:707-13.
19. Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med 2012;271: 499-509.
20. Huang SP, Huang LC, Ting WC, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009;18:3068-74.
21. Zhang MW, Jin MJ, Yu YX, et al. Associations of lifestyle-related factors, hsa-miR-149 and hsamiR-605 gene polymorphisms with gastrointestinal cancer risk. Mol Carcinog 2012;51(Suppl 1): E21-31.
22. Xiao J, Lin H, Luo X, et al. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011;30:524-32.
23. Gabra H, Watson JE, Taylor KJ, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996; 56:950-4.
24. Negrini M, Rasio D, Hampton GM, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res 1995;55:3003-7.
25. Rasio D, Negrini M, Manenti G, et al. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res 1995;55:3988-91.
26. Hayashi T, Oue N, Sakamoto N, et al. Identification of transmembrane protein in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of CDON is involved in tumor cell growth and invasion. Pathobiology 2011;78:277-84.
27. Bao BY, Pao JB, Huang CN, et al. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 2011;17:928-36.